Switch theme
Sign up to access all valuation multiples
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
2019
41
LTM Revenue n/a
LTM EBITDA -$82.9M
$586M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sionna Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$82.9M.
In the most recent fiscal year, Sionna Therapeutics achieved revenue of n/a and an EBITDA of -$69.9M.
Sionna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sionna Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$49.8M | -$69.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$40.2M | -$47.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sionna Therapeutics's stock price is $9.
Sionna Therapeutics has current market cap of $393M, and EV of $586M.
See Sionna Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $586M | $393M | XXX | XXX | XXX | XXX | $-12.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sionna Therapeutics has market cap of $393M and EV of $586M.
Sionna Therapeutics's trades at n/a LTM EV/Revenue multiple, and -7.1x LTM EBITDA.
Analysts estimate Sionna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sionna Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $586M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -8.4x | XXX | XXX | XXX |
| P/E | -6.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -11.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSionna Therapeutics's NTM/LTM revenue growth is n/a
Sionna Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.
Over next 12 months, Sionna Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sionna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sionna Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sionna Therapeutics acquired XXX companies to date.
Last acquisition by Sionna Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sionna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sionna Therapeutics founded? | Sionna Therapeutics was founded in 2019. |
| Where is Sionna Therapeutics headquartered? | Sionna Therapeutics is headquartered in United States of America. |
| How many employees does Sionna Therapeutics have? | As of today, Sionna Therapeutics has 41 employees. |
| Who is the CEO of Sionna Therapeutics? | Sionna Therapeutics's CEO is Mr. Michael Cloonan. |
| Is Sionna Therapeutics publicy listed? | Yes, Sionna Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sionna Therapeutics? | Sionna Therapeutics trades under SION ticker. |
| When did Sionna Therapeutics go public? | Sionna Therapeutics went public in 2025. |
| Who are competitors of Sionna Therapeutics? | Similar companies to Sionna Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sionna Therapeutics? | Sionna Therapeutics's current market cap is $393M |
| What is the current EBITDA of Sionna Therapeutics? | Sionna Therapeutics's last 12-month EBITDA is -$82.9M. |
| What is the current EV/EBITDA multiple of Sionna Therapeutics? | Current EBITDA multiple of Sionna Therapeutics is -7.1x. |
| Is Sionna Therapeutics profitable? | Yes, Sionna Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
